芪苈强心胶囊治疗射血分数保留的心力衰竭疗效的Meta分析

Meta-analysis of the effect of Qiliqiangxin capsules for patients with heart failure and preserved ejection fraction

目的系统评价芪苈强心胶囊治疗射血分数保留的心力衰竭(HFpEF)的疗效。方法系统检索中国知网、万方医学网和维普等数据库检索时间为自建库至2015年3月1日,收集芪苈强心胶囊治疗HFpEF的随机对照试验(RCT)。采用RevMan 5.2.0软件进行统计分析。结果共纳入10篇文献患者829例。Meta分析结果;在常规治疗基础上,加用芪苈强心胶囊有助于进一步改善心功能(RR=1.41,95%CI 1.15~1.71,P<0.01)和E/A值(WMD=0.14,95%CI 0.07~0.21,P<0.01),提高6 min步行距离(WMD=67.40,95%CI 2.17~132.63,P=0.04),降低脑钠肽(WMD=-93.46,95%CI-121.98^-64.93,P<0.01)和氨基末端脑钠肽前体(WMD=-543.45,95%CI-924.25^-162.65,P<0.01)水平。结论芪苈强心胶囊治疗HFpEF疗效好,安全性高,值得临床推广。

Objective To systemic evaluate the effect of Qiliqiangxin capsules in the treatment of heart failure with preserved ejection fraction （HFpEF）.Methods Systemic retrieval CNKI, Wanfang medicine and VIP database from data-base self-building to March 1, 2015, collected randomized controlled trials （RCT） of Qiliqiangxin capsules in the treatment of HFpEF.Statistical analysis were performed using 5.2.0 RevMan software.Results A total of 10 articles （829 cases） were included.Meta-analysis showed that, on the basis of routine treatment, the Qiliqiangxin capsules can help to further improve the cardiac function （RR=1.41, 95%CI 1.15 to 1.71, P 〈0.01）, E/a value （WMD=0.14, 95% CI 0.07 to 0.21, P 〈0.01）, and 6 min walking distance （WMD=67.40, 95%CI 2.17 to 132.63, P =0.04）, also reduced the brain natri-uretic peptide （WMD=-93.46, 95%CI -121.98 to -64.93, P 〈0.01） and N-terminal pro brain natriuretic peptide （WMD=-543.45, 95%CI -924.25 to -162.65, P 〈0.01） level.Conclusion Qiliqiangxin capsules has good cura-tive effect in the treatment of HFpEF wiht high safety , which is worthy of promotion .